Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1Phase 1 1

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Pancreatic Neoplasms 5Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Triple Negative Breast Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma 2Leukemia, Myeloid, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Carcinoma, Transitional Cell 2Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms, Plasma Cell 1Neoplasm, Residual 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Melanoma 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lung Neoplasms 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1

Interventions

pembrolizumab 26Nivolumab 10Cisplatin 9Gemcitabine 8Docetaxel 6enfortumab vedotin 5atezolizumab 5Ipilimumab 5Carboplatin 5sacituzumab govitecan 4Paclitaxel 4Pemetrexed 3Cyclophosphamide 3vofatamab 2tremelimumab 2tislelizumab 2regorafenib 2lenvatinib 2epacadostat 2durvalumab 2avelumab 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Leucovorin 2Biopsy 2Bevacizumab 2B701 protein, Human herpesvirus 6 2ALT-803 2yeast-CEA vaccine 1toripalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Transitional Cell × ALT-803 × Clear all
NCT02138734 2026-03-31

A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

ImmunityBio, Inc.

Phase 1/2 Active not recruiting
369 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms

NCT03197571 2025-02-21

QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

ImmunityBio, Inc.

Phase 1/2 Withdrawn
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡